Edesa Biotech (EDSA) Competitors

$14.47 -0.77 (-5.05%)

As of 02:45 PM Eastern

EDSA vs. PROK, TECX, EIKN, ALLO, and CADL

Should you buy Edesa Biotech stock or one of its competitors? MarketBeat compares Edesa Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edesa Biotech include ProKidney (PROK), Tectonic Therapeutic (TECX), EIKN (EIKN), Allogene Therapeutics (ALLO), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does Edesa Biotech compare to ProKidney?

Edesa Biotech (NASDAQ:EDSA) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Edesa Biotech presently has a consensus price target of $5.00, suggesting a potential downside of 65.45%. ProKidney has a consensus price target of $7.40, suggesting a potential upside of 331.49%. Given ProKidney's stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, ProKidney had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 4 mentions for ProKidney and 3 mentions for Edesa Biotech. ProKidney's average media sentiment score of 0.72 beat Edesa Biotech's score of 0.30 indicating that ProKidney is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edesa Biotech has higher earnings, but lower revenue than ProKidney. Edesa Biotech is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.15	N/A
ProKidney	$890K	581.79	-$68.99M	-$0.52	N/A

Edesa Biotech has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

Edesa Biotech has a net margin of 0.00% compared to ProKidney's net margin of -7,725.20%. ProKidney's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-163.57%	-52.54%
ProKidney	-7,725.20%	N/A	-18.83%

Summary

ProKidney beats Edesa Biotech on 14 of the 16 factors compared between the two stocks.

How does Edesa Biotech compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Tectonic Therapeutic currently has a consensus price target of $80.57, indicating a potential upside of 167.99%. Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 65.45%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, equities analysts plainly believe Tectonic Therapeutic is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Edesa Biotech is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.15	N/A

Tectonic Therapeutic has a beta of 3.27, meaning that its share price is 227% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Tectonic Therapeutic's return on equity of -32.33% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Edesa Biotech	N/A	-163.57%	-52.54%

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Tectonic Therapeutic had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 5 mentions for Tectonic Therapeutic and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.30 beat Tectonic Therapeutic's score of 0.13 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tectonic Therapeutic beats Edesa Biotech on 11 of the 14 factors compared between the two stocks.

How does Edesa Biotech compare to EIKN?

EIKN (NASDAQ:EIKN) and Edesa Biotech (NASDAQ:EDSA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

EIKN presently has a consensus price target of $25.20, indicating a potential upside of 89.54%. Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 65.45%. Given EIKN's stronger consensus rating and higher probable upside, research analysts clearly believe EIKN is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

EIKN's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EIKN	N/A	N/A	N/A
Edesa Biotech	N/A	-163.57%	-52.54%

5.5% of Edesa Biotech shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, EIKN had 3 more articles in the media than Edesa Biotech. MarketBeat recorded 6 mentions for EIKN and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.30 beat EIKN's score of -0.46 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
EIKN	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EIKN	N/A	N/A	N/A	N/A	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.15	N/A

Summary

EIKN beats Edesa Biotech on 6 of the 9 factors compared between the two stocks.

How does Edesa Biotech compare to Allogene Therapeutics?

Edesa Biotech (NASDAQ:EDSA) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Edesa Biotech has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Edesa Biotech has higher earnings, but lower revenue than Allogene Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.15	N/A
Allogene Therapeutics	$20K	26,159.02	-$190.89M	-$0.87	N/A

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Allogene Therapeutics had 8 more articles in the media than Edesa Biotech. MarketBeat recorded 11 mentions for Allogene Therapeutics and 3 mentions for Edesa Biotech. Allogene Therapeutics' average media sentiment score of 0.67 beat Edesa Biotech's score of 0.30 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics' return on equity of -57.07% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-163.57%	-52.54%
Allogene Therapeutics	N/A	-57.07%	-41.63%

Edesa Biotech currently has a consensus price target of $5.00, indicating a potential downside of 65.45%. Allogene Therapeutics has a consensus price target of $8.07, indicating a potential upside of 277.63%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

Allogene Therapeutics beats Edesa Biotech on 12 of the 15 factors compared between the two stocks.

How does Edesa Biotech compare to Candel Therapeutics?

Edesa Biotech (NASDAQ:EDSA) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Edesa Biotech presently has a consensus price target of $5.00, suggesting a potential downside of 65.45%. Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 109.81%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Candel Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Candel Therapeutics' return on equity of -51.44% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-163.57%	-52.54%
Candel Therapeutics	N/A	-51.44%	-36.31%

In the previous week, Candel Therapeutics had 4 more articles in the media than Edesa Biotech. MarketBeat recorded 7 mentions for Candel Therapeutics and 3 mentions for Edesa Biotech. Candel Therapeutics' average media sentiment score of 0.57 beat Edesa Biotech's score of 0.30 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edesa Biotech is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.15	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.71	N/A

Edesa Biotech has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.59, meaning that its share price is 159% less volatile than the broader market.

Summary

Candel Therapeutics beats Edesa Biotech on 10 of the 13 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDSA vs. The Competition

Export

Metric	Edesa Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$128.59M	$3.40B	$6.29B	$12.48B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-12.58	18.81	20.91	25.60
Price / Sales	N/A	284.65	548.78	75.41
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	32.16	6.78	9.87	6.72
Net Income	-$7.19M	$24.11M	$3.55B	$333.73M
7 Day Performance	-16.98%	0.22%	-0.24%	0.38%
1 Month Performance	177.20%	1.08%	1.44%	4.02%
1 Year Performance	612.81%	78.09%	41.01%	36.37%

Edesa Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDSA Edesa Biotech	1.5765 of 5 stars	$14.47 -5.0%	$5.00 -65.4%	+662.0%	$128.59M	N/A	N/A	20	Short Interest Increase
PROK ProKidney	1.8507 of 5 stars	$1.92 +2.1%	$7.40 +285.4%	+101.5%	$567.60M	$890K	N/A	3
TECX Tectonic Therapeutic	2.2353 of 5 stars	$29.36 -1.0%	$80.57 +174.4%	+42.7%	$558.86M	N/A	N/A	120	Earnings Report
EIKN EIKN	N/A	$10.28 +0.1%	$25.60 +149.0%	N/A	$556.55M	N/A	N/A	384	News Coverage Earnings Report Analyst Forecast
ALLO Allogene Therapeutics	3.4841 of 5 stars	$2.17 -4.0%	$8.44 +288.9%	+106.2%	$553.28M	$20K	N/A	310	Trending News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDSA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edesa Biotech (EDSA) Competitors

EDSA vs. PROK, TECX, EIKN, ALLO, and CADL

How does Edesa Biotech compare to ProKidney?

Summary

How does Edesa Biotech compare to Tectonic Therapeutic?

Summary

How does Edesa Biotech compare to EIKN?

Summary

How does Edesa Biotech compare to Allogene Therapeutics?

Summary

How does Edesa Biotech compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edesa Biotech (EDSA) Competitors

EDSA vs. PROK, TECX, EIKN, ALLO, and CADL

How does Edesa Biotech compare to ProKidney?

Do analysts rate EDSA or PROK?

Do institutionals and insiders hold more shares of EDSA or PROK?

Does the media favor EDSA or PROK?

Which has stronger earnings and valuation, EDSA or PROK?

Which has more risk and volatility, EDSA or PROK?

Is EDSA or PROK more profitable?

Summary

How does Edesa Biotech compare to Tectonic Therapeutic?

Do analysts prefer TECX or EDSA?

Which has better valuation and earnings, TECX or EDSA?

Which has more risk & volatility, TECX or EDSA?

Is TECX or EDSA more profitable?

Do institutionals & insiders have more ownership in TECX or EDSA?

Does the media favor TECX or EDSA?

Summary

How does Edesa Biotech compare to EIKN?

Do analysts rate EIKN or EDSA?

Is EIKN or EDSA more profitable?

Do insiders and institutionals believe in EIKN or EDSA?

Does the media favor EIKN or EDSA?

Which has better valuation & earnings, EIKN or EDSA?

Summary

How does Edesa Biotech compare to Allogene Therapeutics?

Which has more volatility & risk, EDSA or ALLO?

Which has better earnings and valuation, EDSA or ALLO?

Do institutionals & insiders believe in EDSA or ALLO?

Does the media favor EDSA or ALLO?

Is EDSA or ALLO more profitable?

Do analysts prefer EDSA or ALLO?

Summary

How does Edesa Biotech compare to Candel Therapeutics?

Do analysts prefer EDSA or CADL?

Do institutionals and insiders have more ownership in EDSA or CADL?

Is EDSA or CADL more profitable?

Does the media refer more to EDSA or CADL?

Which has higher earnings & valuation, EDSA or CADL?

Which has more volatility and risk, EDSA or CADL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools